Placebo News and Research

RSS

Omega-3 supplements, sertraline could help prevent onset of depression and dementia in later life

A University of Sydney study is looking into the effectiveness of omega-3 supplements and the antidepressant, sertraline, in reducing depressive symptoms and cognitive decline in older people, in a bid to prevent the onset of depression and dementia in later life.

24 Feb 2014

Vitamin E supplements and selenium may increase prostate cancer risk

In a large clinical trial testing dietary supplements for prostate cancer (PCa) prevention, baseline selenium (Se) status (measured by toenail Se concentration), in the absence of supplementation, was not associated with prostate cancer (PCa) risk.

24 Feb 2014

LJPC completes dosing in Phase 2 clinical trial of GCS-100 for treatment of chronic kidney disease

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has completed dosing of its Phase 2 clinical trial of GCS-100 for the treatment of chronic kidney disease ("CKD") and has collected the final data for evaluation of the primary endpoint.

23 Feb 2014

Study determines effectiveness of gabapentin for treatment of vulvodynia in women

A chronic syndrome called vulvodynia that affects from four to seven percent of women is being studied by physicians at The Women's Health Institute at Robert Wood Johnson Medical School, part of Rutgers, The State University of New Jersey, in hopes of alleviating sometimes excruciating pain.

21 Feb 2014

Study indicates relationship between multivitamin supplement use and cataract risk in men

Long-term daily multivitamin supplement use may lower cataract risk in men, according to a study of nearly 15,000 male physicians published this month in Ophthalmology, the journal of the American Academy of Ophthalmology

21 Feb 2014

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

CSL Behring today announced it has enrolled the first patient in COMPACT, an international phase III study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor oncentrate in patients with frequent hereditary angioedema attacks (NCT01912456).

20 Feb 2014

OrthoTrophix commences TPX-100 Phase 2 clinical study in knee osteoarthritis patients

OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company started a Phase 2 clinical study of its cartilage repair therapeutic agent, TPX-100, with knee osteoarthritis patients in the U.S. The Company also announced that it had successfully closed the second and last tranche of its Series A preferred stock financing.

20 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report in the Feb. 20 issue of the New England Journal of Medicine.

20 Feb 2014

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga® (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases.

20 Feb 2014

Antidepressant medication shows potential in treating symptoms of agitation that occur with AD

An antidepressant medication has shown potential in treating symptoms of agitation that occur with Alzheimer's disease and in alleviating caregivers' stress, according to a multi-site U.S.- Canada study.

20 Feb 2014

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Nintedanib plus docetaxel offers significant efficacy in patients with non-small-cell lung cancer who experience disease progression after first-line chemotherapy, phase III study results show.

19 Feb 2014

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.

19 Feb 2014

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.

18 Feb 2014

GENFIT receives FDA Fast Track designation for GFT505 development program in NASH

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that the Food and Drug Administration has granted Fast Track designation to the GFT505 development program in NASH, with effect from February 14, 2014.

18 Feb 2014

Altrient C improves skin firmness and elasticity by 32.7%

...

17 Feb 2014

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014.

16 Feb 2014

Research findings have important implications for personalized treatment of alcohol abuse

Heavy drinking is common in the United States and takes a personal and societal toll, with an annual estimated cost of $223.5 billion due to losses in workplace productivity, health care and criminal justice expenses.

16 Feb 2014

Topiramate reduces drinking in patients committed to abstinence from alcohol

Heavy drinking alcohol consumption is common in the United States and takes a personal and societal toll, with an annual estimated cost of $223.5 billion due to losses in workplace productivity, and health care and criminal justice expenses.

14 Feb 2014

FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

A report in the Feb. 13 New England Journal of Medicine confirms previous studies suggesting that long-term treatment with the type of drugs commonly prescribed to treat restless leg syndrome (RLS) can cause a serious worsening of the condition in some patients.

14 Feb 2014

Placebo News and Research

Omega-3 supplements, sertraline could help prevent onset of depression and dementia in later life

Vitamin E supplements and selenium may increase prostate cancer risk

LJPC completes dosing in Phase 2 clinical trial of GCS-100 for treatment of chronic kidney disease

Study determines effectiveness of gabapentin for treatment of vulvodynia in women

Study indicates relationship between multivitamin supplement use and cataract risk in men

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

OrthoTrophix commences TPX-100 Phase 2 clinical study in knee osteoarthritis patients

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Antidepressant medication shows potential in treating symptoms of agitation that occur with AD

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Omeros doses first patient in second Phase 2 clinical trial of OMS824

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

GENFIT receives FDA Fast Track designation for GFT505 development program in NASH

Altrient C improves skin firmness and elasticity by 32.7%

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Research findings have important implications for personalized treatment of alcohol abuse

Topiramate reduces drinking in patients committed to abstinence from alcohol

FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News